Reduction in cervical intraepithelial neoplasia in young women in<scp>B</scp>ritish<scp>C</scp>olumbia after introduction of the<scp>HPV</scp>vaccine: An ecological analysis

Naus, Monika; Money, Deborah; Dobson, Simon; Miller, D. Craig; Krajden, Mel; Niekerk, Dirk J. van; Coldman, Andrew J.

doi:10.1002/ijc.29508

Cited by 39 publications

(42 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The study observed a significant decrease in the incidence of high-grade abnormalities in young girls younger (< 18 years) after implementing the HPV vaccination program in Australia. A Canadian study conducted by Ogilvie et al [55] achieved similar results. The study reported the rates of CIN in young women (aged 15–22 years) living in British Columbia before and after the introduction of an HPV vaccine program (in 2007).…”

Section: Data From Real Worldsupporting

confidence: 71%

HPV Vaccine: Updates and Highlights

2019

View full text Add to dashboard Cite

HPV is the most common sexually transmitted biological agent and is the cause of many conditions in men and women, including precancer lesions and cancer. Three prophylactic HPV vaccines targeting high-risk HPV types are available in many countries worldwide: 2-, 4- and 9-valent vaccines. All the 3 vaccines use recombinant DNA technology and are prepared from the purified L1 protein that self-assembles to form HPV type-specific empty shells. This non-systematic review aims to summarize the HPV epidemiology and the vaccine development to review the landmark trials of HPV vaccine, to present to most remarkable results from clinical trials and the real world, and to stress the challenges and the barriers for HPV vaccine implementation.

show abstract

Section: Data From Real Worldsupporting

confidence: 71%

HPV Vaccine: Updates and Highlights

2019

View full text Add to dashboard Cite

show abstract

“…The early protection offered by the vaccine at the population level against vaccine-targeted HPV infections, genital warts and cervical premalignant lesions has been reported from countries that introduced the vaccine between 2007 and 20104849505152535455. In Denmark, the atypia or worse and CIN2 or worse lesions increased in all age groups during 2000-2010, the incidence of such lesions decreased significantly in women younger than 18 yr [estimated annual percentage change (EAPC) - 33.4%; 95% CI -49.6; -12.0] and in 18-20 yr old women (EAPC - 12.6%; 95% CI -19.3; -5.3), after the introduction of HPV vaccination programme; however, no significant decrease was seen in older age groups50.…”

Section: Effectiveness Of Hpv Vaccine In the National Immunization Prmentioning

confidence: 99%

Current global status & impact of human papillomavirus vaccination

Sankaranarayanan¹,

Bhatla²,

Basu³

2016

Indian Journal of Medical Research

View full text Add to dashboard Cite

This review addresses the effectiveness and safety of human papillomavirus (HPV) vaccines, the current status of its introduction in the National Immunization Programmes (NIPs) and its relevance to India, which contributes a fifth of the global burden of cervical cancer. The vast literature on efficacy, acceptability and safety of HPV vaccination and its impact after population level introduction was reviewed and discussed. The efficacy of HPV vaccines in preventing high-grade precancerous lesions caused by vaccine-targeted HPV infections was 90 per cent or higher in HPV naïve women in randomized clinical trials. Two doses at 6 or 12 months apart are recommended for 9-14 yr old girls and three doses over six months to one year period for those aged above 15 yr. More than 80 countries or territories have introduced HPV vaccination in their NIPs, of which 33 are low- and middle-income countries (LMICs); in addition, 25 LMICs have introduced pilot programmes before a phased national expansion. Significant reductions in the frequency of HPV 16 and 18 infections, genital warts and cervical premalignant lesions in vaccinated cohorts and herd immunity in general populations have been reported from countries that introduced vaccination in NIPs as early as 2007. More than 280 million doses of HPV vaccines have been administered worldwide with the excellent safety profile with no serious adverse events linked to it. The high burden of cervical cancer and the high efficacy and safety of HPV vaccination justify its introduction in the Indian NIP at the earliest possibility to substantially reduce the cervical cancer burden in future.

show abstract

“…Epidemiological studies from Australia, Canada, UK and the US demonstrate population level reductions in the rates of HPV, GW, and cervical cancer lesions after introduction of HPV vaccine programs for girls [6–11]. With strong empirical evidence for both vaccine safety and efficacy [5], the HPV vaccine is an important innovation in cancer prevention [6, 12]. …”

Section: Introductionmentioning

confidence: 99%

Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study

et al. 2016

View full text Add to dashboard Cite

BackgroundHPV vaccination decision-making is a complex process that is influenced by multiple psychosocial determinants. Given the change in policy recommendation to include males in routine HPV vaccination, our goals were to assess the HPV vaccination uptake in Canada, to understand where Canadian parents were situated in the HPV vaccine decision-making process for their son, how they changed over time and which psychosocial determinants were relevant for this process.MethodsWe used an online survey methodology and collected data from a nationally representative sample of Canadian parents of boys aged 9–16 at baseline (T1, February 2014) and at 9 months’ follow-up (T2). Our analyses were guided by the Precaution Adoption Process Model (PAPM), a theoretical health behavior model that classifies parents in one of six stages: unaware, unengaged, undecided, decided not to vaccinate, decided to vaccinate and those who had already vaccinated their sons. Rigorous methods were used to filter out careless responders: response variance, bogus items, psychometric antonyms and psychometric synonyms.ResultsAt T1 and T2, we received 3,784 and 1,608 respectively completed questionnaires; after data cleaning 3,117 (T1) and 1,427 (T2) were retained. Less than 3% of boys were vaccinated at both time points. At both T1 and T2, most parents (over 70%) belonged to the earlier vaccination adoption stages: 57% were unaware (T1) and 15.3% (T2); 20.9% were unengaged (T1) and 32.4% (T2); and 9.1% were undecided (T1) and 25.2% (T2). At follow-up, 37.7% of participants did not move from their initial PAPM decision-making stage. Most parents (55%) preferred to receive information from their healthcare provider (HCP) but only 6% (T1) and 12% (T2) had actually spoken with a HCP about the HPV vaccine for their son.ConclusionsHPV vaccination uptake in Canadian boys was very low in the absence of a publicly funded HPV vaccination programs for boys. Optimal HPV information preferences were identified and can be used in interventions to increase HPV knowledge and increase HPV vaccine uptake. Intentions to vaccinate or planning to speak to one’s HCP did not translate into action for most parents over the 9-month follow up; this finding is critical to consider to inform implementation strategies. Methodological challenges are described and suggestions for future research are offered.Electronic supplementary materialThe online version of this article (doi:10.1186/s12889-016-3828-9) contains supplementary material, which is available to authorized users.

show abstract

Reduction in cervical intraepithelial neoplasia in young women inBritishColumbia after introduction of theHPVvaccine: An ecological analysis

Cited by 39 publications

References 21 publications

HPV Vaccine: Updates and Highlights

HPV Vaccine: Updates and Highlights

Current global status & impact of human papillomavirus vaccination

Psychosocial determinants of parental human papillomavirus (HPV) vaccine decision-making for sons: Methodological challenges and initial results of a pan-Canadian longitudinal study

Contact Info

Product

Resources

About